Conatus Pharmaceuticals, Inc. (CNAT)

Conatus-Pharma-logoConatus Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes novel medicines for the treatment of liver disease. Conatus develops emracasan, the company’s lead compound for treating patients suffering from chronic liver disease, as well as acute exacerbations of chronic liver disease. An orally active pan-caspase protease inhibitor, emracasan is designed for reduction of the activity of ten human caspases, the enzymes mediating inflammation and death of cells, or apoptosis.

The company believes that emracasan has the capability to interrupt the progress of liver disease, and can provide options for treatment in various areas of liver disease based on the preclinical and clinical trial results suggesting that emracasan has the potential to slow the progression of liver disease, regardless of its original cause. Emracasan has been studied in ten clinical trials with more than 500 subjects.

In the Phase 2b of clinical trial in liver disease patients, emracasan has demonstrated a consistent, rapid, significant, and sustained reduction of elevated levels of alanine aminotransferase (ALT) and cleaved Cytokeratin 18 (cCK18), the two key biomarkers of cell death and inflammation that are implicated in the progression and severity of liver disease.

Conatus Pharmaceuticals, Inc. has designed a clinical program demonstrating emracasan’s therapeutic benefits across the spectrum of fibrotic liver disease. The company’s strategy focuses on targeting of indications for emracasan in small patient populations, including the small population of patients with chronic liver failure (CLF), and acute-on-chronic liver failure (ACLF).

Conatus Pharmaceuticals, Inc. is traded in the OTC markets under the stock symbol CNAT. The company is committed to serving the best interests of their shareholders. They provide key shareholder information and financial reports to help put the company’s financial performance into perspective.

Yahoo! Finance: CNAT News

Latest Financial News for CNAT

Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

Conatus Pharmaceuticals Inc. (CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14, was also selected by EASL for inclusion in the “Best of ILC” summary slide deck highlighting the most noteworthy contributions to the scientific program at this year’s meeting. The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) detailed results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor.

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Biotech stocks ended higher for the second straight week, with the presentations at the American Association of Cancer Research annual meeting taking the spotlight. Additionally, there were clinical trial ...

Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

Conatus Pharmaceuticals Inc. (CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9 in London). Conatus senior management will conduct a series of scheduled meetings with investment professionals and present a company overview on Tuesday, April 9, 2019, from 10:30 a.m. to 10:50 a.m. BST (5:30 a.m. to 5:50 a.m. EDT). Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need.

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

Key highlights of the past week are multiple study failures and other pipeline updates.